#USA #San Diego #Halia Therapeutics #David Bearss #Obesity Summit

Halia CEO Dr. David Bearss to Lead Discussions at the Obesity Innovation Therapeutics Summit 2024

Halia Therapeutics, a leading clinical-stage biopharmaceutical firm focused on innovative treatments for chronic diseases, is set to showcase its latest advancements in obesity therapeutics at the 2024 Obesity Innovation Therapeutics Summit. Scheduled for December 10-12 in San Diego, this summit brings together experts to discuss groundbreaking developments in the field, attracting significant attention from healthcare professionals and researchers alike.

Key Presentation on Oral Obesity Therapeutics

One of the highlights of the summit will be a presentation by Dr. David J. Bearss, Co-Founder, President, and CEO of Halia Therapeutics. Dr. Bearss will deliver cutting-edge data on oral obesity therapeutics aimed at shifting the paradigm away from injectable treatments. The details of his presentation are as follows:

• - Title: Patient-Centric Development: Exploring Oral Obesity Therapeutics to Move Away from Injectable Peptides
• - Date: December 11, 2024
• - Time: 5 PM PT

In his talk, Dr. Bearss aims to emphasize patient-centric development approaches, discussing how oral therapies can improve adherence and outcomes in obesity treatment. The data presented is expected to provide invaluable insights into the potential of these new methodologies in treating obesity effectively.

Panel Discussion on Supply Chain Challenges

Apart from his presentation, Dr. Bearss will also participate in a panel discussion titled "The Obesity Race on the Manufacturing Floor – Exploring Supply Challenges with Innovations in Discovery". This session, scheduled for the same day at 2:40 PM PT, will explore current supply chain challenges within the obesity therapeutics landscape and the innovative solutions to overcome them. Other prominent panelists include:

• - Feng Liu, Executive Director of Research Development, Regor Pharmaceuticals
• - Adam Mendelsohn, CEO of Vivani Medical

The insights shared during this discussion are expected to shine a light on the complexities faced within the manufacturing and distribution of anti-obesity therapeutics, encouraging dialogue around improvements in these areas.

Halia Therapeutics' Commitment to Innovation

Halia Therapeutics is dedicated to transforming the future of treatment for chronic inflammatory and neurodegenerative diseases with its innovative therapeutic pipeline. Currently, Halia’s leading candidate, HT-6184, has shown promising results in Phase I clinical trials and is advancing toward Phase II studies. The ongoing development of HT-6184 showcases Halia's commitment to addressing unmet medical needs in both inflammation and obesity.

Additionally, the company has initiated a Phase I trial for HT-4253, a novel LRRK2 inhibitor designed to target neurodegenerative conditions, reflecting its innovative spirit and commitment to scientific advancement in the healthcare sector.

Located in Lehi, Utah, Halia Therapeutics is poised to advance healthcare through science and technology. For more information, visit their website Halia Therapeutics and follow them on social media platforms to stay updated on their progress and contributions to the industry.

Conclusion

The Obesity Innovation Therapeutics Summit presents a significant opportunity for Halia Therapeutics to highlight its developments and establish new collaborations with other leaders in the field. Dr. Bearss's participation underscores not only the company’s innovative approach but also its commitment to enhancing patient care in the realm of obesity treatment— a growing health concern worldwide.